Prostate Cancer Clinical Trial
Official title:
Randomized Trial of Adjuvant Curcumin After Prostatectomy
NCT number | NCT02064673 |
Other study ID # | STU 042013-080 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | May 2014 |
Est. completion date | June 2026 |
This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.
Status | Recruiting |
Enrollment | 608 |
Est. completion date | June 2026 |
Est. primary completion date | June 2025 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 30 Years to 80 Years |
Eligibility | Inclusion Criteria: - Status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate - pathologically confirmed T1-T3 disease - no sign of lymph node or metastatic disease - pT1-pT3pNxMx patients in whom standard NCCN or AUA guidelines would suggest are at low risk for pelvic lymph node or metastatic disease and who would not require confirmatory imaging for metastatic disease. This includes patients with Gleason 6 or 7(T2 disease) and PSA less than 20. - Eastern Cooperative Oncology Group(ECOG) status 0-2 - adequate renal and liver function as well as bone marrow reserve (measured serum creatinine <2mg/dl, bilirubin = 1.5 mg/dl, ANC = 1.5 x 10 (3) uL, platelets = 50 x K/uLL, and hemoglobin = 10 g/dL) - 30-80 y/o at time of diagnosis with a life expectancy of >= 3 yrs - focally positive surgical margins are permitted - no plan to receive adjuvant hormone or radiation therapy - PSA at the time of enrollment must be undetectable - life expectancy of 3 years Exclusion Criteria: - must not have exceeded 3 months from time of surgery to enrollment into study - T3b or T4 or node positive disease - macroscopic residual disease after surgery - hormone therapy before surgery - history of gallbladder problems or gallstones, or biliary obstruction, unless patient had cholecystectomy - radiation therapy as primary treatment after surgery - INR value greater than 1.5 - AST/ALT are equal or greater than 2 times the upper limit of normal - antiplatelet or anticoagulant agents- patients taking 81mg of Aspirin will be allowed with close observation - history of gastric or duodenal ulcers or untreated hyperacidity syndromes - patients who are currently taking curcumin and are unwilling to stop or plan to take curcumin during the study |
Country | Name | City | State |
---|---|---|---|
United States | UT Southwestern Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
yair lotan |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum prostate specific antigen | Recurrence free survival defined as a total serum prostate specific antigen of <0.2ng/ml. | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |